Beraprost
Top View
- Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
- Project SCYLLA
- Systemic Glucocorticoids in the Treatment of COVID-19 and Risks of Adverse Outcomes in COVID-19 Patients in the Primary and Secondary Care Setting
- Effects of Beraprost Sodium, an Oral Prostacyclin Analogue, in Patients
- Antiplatelet Agents for Chronic Kidney Disease (Review)
- Beraprost Modified Release in Addition to Treprostinil for Pulmonary Arterial Hypertension
- Pharmacological Interventions for the Prevention of Fetal Growth Restriction: Protocol for a Systematic Review and Network Meta-Analysis
- Pulmonary Arterial Hypertension in Children
- Pharmaceutical Compositions Comprising Prasugrel And
- NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Cohort
- Recent Progress and Market Analysis of Anticoagulant Drugs
- Beraprost (Beraprost-314D) on Pulmonary Vascular Tone, IP Receptors and Human Smooth Muscle Proliferation in Pulmonary Hypertension
- Prostanoid Therapy for Pulmonary Arterial Hypertension David B
- Tissue‐Resident Macrophages Actively
- Oral Beraprost Sodium As a Prostaglandin 12
- Tissue‐Resident Macrophages Actively Suppress IL
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Biotechnology Corticosteroids & Hormones Synthesis Prostaglandins